Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Signaling pathways governing tumor angiogenesis.

Sakurai T, Kudo M.

Oncology. 2011;81 Suppl 1:24-9. doi: 10.1159/000333256. Epub 2011 Dec 22. Review.

PMID:
22212932
2.

Targeting angiogenesis in cancer therapy.

Ichihara E, Kiura K, Tanimoto M.

Acta Med Okayama. 2011 Dec;65(6):353-62. Review.

3.

Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.

Gacche RN, Meshram RJ.

Prog Biophys Mol Biol. 2013 Nov;113(2):333-54. doi: 10.1016/j.pbiomolbio.2013.10.001. Epub 2013 Oct 15. Review.

PMID:
24139944
4.

Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.

Zhao Y, Adjei AA.

Oncologist. 2015 Jun;20(6):660-73. doi: 10.1634/theoncologist.2014-0465. Epub 2015 May 22. Review.

5.

Antiangiogenic therapy in malignant glioma: promise and challenge.

Sathornsumetee S, Rich JN.

Curr Pharm Des. 2007;13(35):3545-58. Review.

PMID:
18220791
6.

How do angiopoietins Tie in with vascular endothelial growth factors?

Saharinen P, Bry M, Alitalo K.

Curr Opin Hematol. 2010 May;17(3):198-205. doi: 10.1097/MOH.0b013e3283386673. Review.

PMID:
20375888
7.

Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.

Fernando NT, Koch M, Rothrock C, Gollogly LK, D'Amore PA, Ryeom S, Yoon SS.

Clin Cancer Res. 2008 Mar 1;14(5):1529-39. doi: 10.1158/1078-0432.CCR-07-4126.

8.

Development of new drugs in angiogenesis.

Ziche M, Donnini S, Morbidelli L.

Curr Drug Targets. 2004 Jul;5(5):485-93. Review.

PMID:
15216914
9.

Angiogenesis--a new target for future therapy.

Pandya NM, Dhalla NS, Santani DD.

Vascul Pharmacol. 2006 May;44(5):265-74. Epub 2006 Mar 20. Review.

PMID:
16545987
10.

TGF-β receptor signaling pathways in angiogenesis; emerging targets for anti-angiogenesis therapy.

van Meeteren LA, Goumans MJ, ten Dijke P.

Curr Pharm Biotechnol. 2011 Dec;12(12):2108-20. Review.

PMID:
21619534
11.

VEGF and angiopoietin signaling in tumor angiogenesis and metastasis.

Saharinen P, Eklund L, Pulkki K, Bono P, Alitalo K.

Trends Mol Med. 2011 Jul;17(7):347-62. doi: 10.1016/j.molmed.2011.01.015. Epub 2011 Apr 12. Review.

PMID:
21481637
12.

Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.

Shinkaruk S, Bayle M, Laïn G, Déléris G.

Curr Med Chem Anticancer Agents. 2003 Mar;3(2):95-117. Review.

PMID:
12678905
13.

Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.

Pradeep CR, Sunila ES, Kuttan G.

Integr Cancer Ther. 2005 Dec;4(4):315-21. Review.

PMID:
16282508
14.

Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.

Zhang L, Yang N, Park JW, Katsaros D, Fracchioli S, Cao G, O'Brien-Jenkins A, Randall TC, Rubin SC, Coukos G.

Cancer Res. 2003 Jun 15;63(12):3403-12.

15.

Delta-like 4/Notch signaling and its therapeutic implications.

Yan M, Plowman GD.

Clin Cancer Res. 2007 Dec 15;13(24):7243-6. Review.

16.

Pathophysiology of tumor neovascularization.

Furuya M, Nishiyama M, Kasuya Y, Kimura S, Ishikura H.

Vasc Health Risk Manag. 2005;1(4):277-90. Review.

17.

Tumor angiogenesis: molecular pathways and therapeutic targets.

Weis SM, Cheresh DA.

Nat Med. 2011 Nov 7;17(11):1359-70. doi: 10.1038/nm.2537. Review.

PMID:
22064426
19.

Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis.

Larsen AK, Ouaret D, El Ouadrani K, Petitprez A.

Pharmacol Ther. 2011 Jul;131(1):80-90. doi: 10.1016/j.pharmthera.2011.03.012. Epub 2011 Mar 23. Review.

PMID:
21439312
20.

Angiogenic growth factors and their inhibitors in diabetic retinopathy.

Praidou A, Androudi S, Brazitikos P, Karakiulakis G, Papakonstantinou E, Dimitrakos S.

Curr Diabetes Rev. 2010 Sep;6(5):304-12. Review.

PMID:
20594164
Items per page

Supplemental Content

Write to the Help Desk